An interventional study of Paclitaxel Coated Peripheral Angioplasty Balloon Catheter in Popliteal Artery Stenosis Above the Knee, Peripheral Artery Disease and Superficial Femoral Artery Stenosis, sponsored by Balton Sp.zo.o.. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Balton Sp.zo.o. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Peripheral Arterial Disease with a site in Poland — 7 open to participants now, 9 under way, 3 of them phase 3. Peripheral Arterial Disease · Poland.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, this one is the 17th largest by planned enrollment of the 28 interventional ones that give a count, is one of 3 that started in 2024, is one of 16 with no phase, and was the 26th registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →7 of the 31 studies in Peripheral Arterial Disease with a site in Poland are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Poland, United States, Argentina and 15 more countries
Ages 18+
Wroclaw Medical University · Sites in Poland
Ages 18+
MDCECRO LLC · Sites in Poland
Ages 18–80
CSL Behring · Sites in Poland, United States, Argentina and 32 more countries
Ages 18+
Grena Biomed Limited · Sites in Poland, Belgium
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 11 · Phase 4 1
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 220 across the 28 interventional studies, 300 across the 3 observational. Of the 21 that completed or were terminated, 10 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 31 have an industry lead sponsor. The 10 most frequent:
Balton Sp.zo.o. is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
Balton Sp.zo.o. has 3 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07157475Wroclaw Medical UniversityVascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors | 2026-12-31 |
| NCT07122167MDCECRO LLCPost-market Registry Study on the Safety and Efficacy of ZENFLEX Pro™ Peripheral Drug-eluting Stent System for Femoropopliteal Artery Lesions | 2026-12-31 |
| NCT04349657KANDO ResearchA Study Evaluating the Endovascular Treatment of Subjects With Stenotic or Restenotic Lesions of the Common Femoral Artery With the Supera Vascular Mimetic Implant Compared to Surgical Common Femoral Artery Endarterectomy | 2027-05 |
| NCT07049120Zhejiang Zylox Medical Device Co., Ltd.Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 31 studies in Peripheral Arterial Disease with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the performance and the safety of the PAK® DCB Catheter in the treatment of de novo and restenotic atherosclerotic lesions in the superficial femoral and/or popliteal arteries (SFA/PA) of patients with symptomatic peripheral artery disease (PAD).
The study enrolls patients who have been diagnosed with peripheral artery disease with stenosis of the superficial femoral or popliteal artery and are qualified for endovascular revascularization.
Lower extremity peripheral artery disease may be asymptomatic or may be accompanied by clinical symptoms due to restricted blood flow to the lower extremities.
The management of a patient diagnosed with peripheral arteriosclerosis is primarily aimed at reducing symptoms of limb ischemia and improving blood supply to the limb, as well as seeking to halt the progression of the disease.
Treatment of lower extremity atherosclerosis with percutaneous methods is a well-known minimally invasive and recommended treatment for lower extremity ischemia.
A maximum of 120 patients will be included in the study. All patients included in the study will receive treatment with the investigational device.
The study will use the PAK balloon catheter, which is CE certified and approved for the treatment of patients with peripheral vascular disease. That is, it is also used as standard outside the study. The test procedure with the study device is in accordance with its registration and instructions for use.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Target Lesion \<150 mm that consists of no more than two adjacent lesions ≤ 25mm apart and is able to be completely covered with inflation of single investigated PAK DCB (with minimum of >5mm proximal and distal margin.
Note: Adjacent or tandem lesions must be treated as a single lesion.
Note: treatment of contralateral iliac arteries is allowed.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Peripheral revascularization procedure using a PAK DCB catheter covered with paclitaxel.
Device: Paclitaxel Coated Peripheral Angioplasty Balloon Catheter
Paclitaxel coated peripheral angioplasty balloon catheters are catheters of "over the wire" (OTW) type. Distal part of the catheter consists of two channels. External channel is used for inflating the balloon, and internal channel is the guide wire. Catheter has two markers enabling precise determination of balloon position in the vessel. The balloon is covered with a coating POLIGRADE® and drug paclitaxel an amount to 2.5 µg/mm2 , which is eluting during balloon inflation. Paclitaxel belongs to alkaloids group from taxanes group. It is cytostatic and it inhibits the cell cycle in G2/M phase. By inhibiting division of cells and their migration, paclitaxel allows for limiting restenosis phenomenon. Paclitaxel selectively inhibits smooth myocytes proliferation, while the endothelium cells show higher resistance to its action. In addition, paclitaxel restricts inflammatory conditions in walls of the arteries after balloon angioplasty.
Also known as: PAK®
Safety - MAEs at 12 months
Major Adverse Events (MAEs) at 12 months defined as the composite of: target-limb-related death, major amputation of the target limb and, re-intervention of the target limb.
Time frame: 12 months
Efficacy-PAK DCB Success at 12 months, defined as primary patency (PP)
PAK DCB Success at 12 months, defined as primary patency (PP) in the absence of clinically driven bail-out stenting (CDBOS), as defined below. Subjects with no CDBOS will be assessed for PP for the purposes of determining True DCB Success. Clinically Driven Bail-Out Stenting (CDBOS): Stents are considered clinically driven when the angiographic core lab determines that a stent was placed after DCB use during the index procedure under the following conditions that were not resolved by prolonged balloon inflation: •Unresolved flow limiting dissection (Type E or F), OR •Residual lumen diameter stenosis \> 50% A subject with a CDBOS fails the True DCB success endpoint regardless of patency outcomes.
Time frame: 12 months
Primary Patency: Subjects who will achieve primary patency by a combination of duplex ultrasound review and no evidence of clinically driven target lesion revascularization (CD-TLR) prior to the study required 12-month DUS as defined below:
Duplex Ultrasound Review: A patent target lesion shows a Peak Systolic Velocity Ratio (PSVR) less than 2.5 by the Duplex Ultrasound DUS core lab or Clinically Driven Target Lesion Revascularization CD-TLR: any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed that was considered clinically driven when both of the following conditions were met: Worsening clinical based on an ankle-brachial index (ABI) decrease≥20%or\>0.15 compared to maximum early postprocedure ABI or documented increase in Rutherford by at least one class if ABI change was unattainable. Angiographic core lab adjudication of the revascularization angiogram confirming that the target lesion prior to re-intervention demonstrated diameter stenosis \>50%.
Time frame: 12 Month
Technical success rate.
Technical success rate defined as successful balloon insertion, balloon inflation and removal.
Time frame: During procedure
Device success defined.
Device success defined as ability to achieve optimal percutaneoustransluminal angioplasty (PTA) outcome (≤30% residual diameter stenosis in post-procedural angiography with no flow-limiting dissection at the target lesion).
Time frame: During procedure
Procedural success.
Procedural success defined as device success with no major complications. (death, myocardial infarction, amputation, stroke).
Time frame: Up to 3 days after index procedure
Rate of CDBOS.
Rate of Clinically Driven Bail-Out Stenting
Time frame: Up to 3 days after index procedure
Primary Patency at 12 months.
Primary Patency at 12 months, defined as target lesion restenosis as determined by DUS (PSVR \< 2.5) and freedom from CD-TLR.
Time frame: 12 months
Secondary Patency at 12 months.
Secondary Patency at 12 months defined by a PSVR less than 2.5 on DUS regardless of the need for TLR.
Time frame: 12 months
Freedom from clinically driven TLR at 30-day follow-up.
Time frame: 30 days
Freedom from clinically driven TLR at 6-month follow-up.
Time frame: 6 months
Freedom from clinically driven TLR at 12-month follow-up.
Time frame: 12 months
Freedom from TVR at 30-day follow-up.
Time frame: 30 days
Freedom from TVR at 6-month follow-up.
Time frame: 6 months
Freedom from TVR at 12-month follow-up.
Time frame: 12 months
All-cause mortality at 30-day follow-up.
Time frame: 30 days
All-cause mortality at 6-month follow-up.
Time frame: 6 months
All-cause mortality at 12-month follow-up.
Time frame: 12 months
Major amputation rate at 30-day follow-up.
Time frame: 30 days
Major amputation rate at 6-month follow-up.
Time frame: 6 months
Major amputation rate at 12-month follow-up.
Time frame: 12 months
Clinical improvement at 30-day follow-up.
Clinical improvement at 30-day follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.
Time frame: 30 days
Clinical improvement at 6-month follow-up.
Clinical improvement at 6-month follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.
Time frame: 6 months
Clinical improvement at 12-month follow-up.
Clinical improvement at 12-month follow-up compared to the baseline, defined by Rutherford classification improved by at least one category if ABI improved by at least 20% or 0.15.
Time frame: 12 months
Plan to share: Undecided
Started Sep 2024 (actual). Primary completion is estimated for Sep 2026, 24 months after the start.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 24 months is below that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balton Sp.zo.o.